Inclusion Criteria:

          -  A Histological or cytological confirmed diagnosis of Stage III-IV NSCLC, with no
             history of anticancer treatment including chemotherapy;

          -  Male or female aged 18-75years;

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0-2;

          -  Life expectancy of at least 3 months;

          -  At least one radiographically measurable lesion per RECIST 1.1;

          -  Willing to join the clinic trail and sign informed consent;

          -  Able to comply with scheduled visits and treatments.

        Exclusion Criteria:

          -  Presence of cerebral metastases;

          -  Confirmed positive for expression of expression of epidermal growth factor receptor
             (EGFR), activin receptor-like kinase (ALK), c-ros oncogene 1 (ROS1) mutation, or
             programmed death-ligand 1 (PD-L1)(tumor proportion score [TPS≥ 50%] in a genetic test;

          -  Participants with malignant pleural effusion underwent intrapleural injection
             chemotherapy;

          -  Current undergoing or preparing for treatment with target therapy;

          -  Current undergoing or preparing for radiotherapy to the thorax;

          -  Current undergoing or preparing treatment with tumor immunotherapy;

          -  Currently undergoing lipid-decreasing treament;

          -  Pregnant or breastfeeding woman;

          -  Fertile patients who are unwilling or unable to take effective contraceptive measures
             during the research period until 6 months after the study end later;

          -  A history of mental disorders；

          -  Severe and uncontrolled organic lesion or infection, including but not limited to
             cardiopulmonary failure and renal failure，which lead to poor tolerance of
             chemotherapy;

          -  Participated in other clinical trials of small molecule research drugs within 28 days
             prior to enrollment, or participated in other clinical trials of large molecule
             research drugs within 3 months before enrollment;

          -  Known allergy or intolerance to study medications;

          -  Considered to be otherwise unsuitable for the clinical study by researchers.